| Fiscal period | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Period End Date | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 |
|---|
| Net Sales | 258.62 | 248.23 | 299.26 | 359.11 | 321.14 | 221.71 | 187.30 | 118.22 | 59.18 | 27.05 |
| Grant revenue | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Revenues | 258.62 | 248.23 | 299.26 | 359.11 | 321.14 | 221.71 | 187.30 | 118.22 | 59.18 | 27.05 |
| Cost of sales | 43.28 | 39.33 | 43.08 | 36.39 | 35.22 | 30.94 | 20.20 | 12.67 | 9.33 | 5.19 |
| Gross Margin | 215.33 | 208.90 | 256.17 | 322.73 | 285.92 | 190.77 | 167.09 | 105.56 | 49.85 | 21.87 |
| Amortization of intangible assets | 0.82 | 1.07 | 1.04 | 1.03 | 1.68 | 2.14 | 0.93 | 0.93 | 1.05 | 1.38 |
| Research and development expenses | 17.34 | 11.72 | 11.14 | 15.77 | 17.90 | 14.34 | 8.41 | 7.05 | 4.84 | 2.89 |
| Acquired in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling, general and administrative expenses | 198.36 | 181.02 | 198.21 | 258.53 | 220.12 | 173.41 | 133.38 | 90.48 | 46.23 | 19.59 |
| Impairment of intangible assets | (0.05) | (1.03) | (0.45) | -- | 0.00 | -- | -- | -- | (0.37) | (1.80) |
| Gain on sale of assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Fair value adjustment of earn-out liability | -- | -- | -- | -- | -- | -- | -- | -- | -- | (1.57) |
| Investigation, restatement and related | (3.79) | (59.47) | (66.50) | (51.32) | -- | -- | -- | -- | -- | -- |
| Operating Income (Loss) | (5.04) | (45.40) | (21.16) | (3.92) | 46.22 | 0.88 | 24.36 | 7.10 | (2.64) | (5.36) |
| Interest expense, net | 4.98 | 7.94 | 4.71 | -- | -- | -- | 0.09 | 0.05 | -- | 0.59 |
| Change in fair value of investment, related party | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest (expense) income, net | -- | -- | -- | 0.53 | (0.09) | -- | -- | -- | (0.05) | -- |
| Other income (expense), net | (0.02) | 0.00 | 0.28 | -- | -- | (0.34) | -- | -- | -- | -- |
| Amortization of debt discount | -- | -- | -- | -- | -- | -- | -- | -- | (1.33) | (1.71) |
| Gain on divestiture | -- | -- | -- | -- | (1.05) | -- | -- | -- | -- | -- |
| Financing expense associated with warrants issued in connection with convertible promissory note | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Financing expense associated with issuance of common stock for registration rights waivers | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Loss on extinguishment of debt | -- | (8.20) | -- | -- | -- | -- | -- | -- | -- | -- |
| Income (loss) before income tax provision | (10.04) | (61.54) | (25.59) | (3.40) | 45.09 | 0.55 | 24.28 | 7.05 | (4.01) | (7.66) |
| Income tax (benefit) provision | 0.25 | (12.26) | (0.01) | 26.58 | (19.64) | 0.16 | (5.17) | 0.83 | 0.10 | -- |
| Net Loss | (10.29) | (49.28) | (25.58) | (29.98) | 64.73 | -- | -- | -- | (4.11) | -- |
| Accretion of redeemable common stock and common stock with registration rights to fair value | 6.14 | 34.04 | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Income (Loss) Available to Common Shareholders | (16.42) | (83.33) | (25.58) | (29.98) | 64.73 | 0.39 | 29.45 | 6.22 | (4.11) | (7.66) |
| Net Earnings Per Share (Basic) | (0.15) | (0.77) | (0.24) | (0.28) | 0.61 | 0.00 | 0.28 | 0.06 | (0.04) | (0.09) |
| Net Earnings Per Share (Diluted) | (0.15) | (0.77) | (0.24) | (0.28) | 0.56 | 0.00 | 0.26 | 0.05 | (0.04) | (0.09) |
| Weighted Average Shares Outstanding (Basic) | 110.35 | 108.26 | 106.95 | 105.60 | 106.12 | 105.93 | 105.93 | 105.79 | 96.29 | 81.65 |
| Weighted Average Shares Outstanding (Diluted) | 110.35 | 108.26 | 106.95 | 105.60 | 116.11 | 112.65 | 113.63 | 113.30 | 96.29 | 81.65 |